等待开盘 06-30 09:30:00 美东时间
+0.220
+3.85%
Eversense 365 CGM system demonstrated superior performance in both open-loop and closed-loop systems, with strong patient adherence and favorable glucometrics over a full year. The system achieved a mean TIR of 66.16% and GMI of 7.16%, outperforming other CGMs. Integration with the twiist AID system showed promising results, with users achieving a mean TIR of 76.08% and GMI of 6.78%. These findings highlight Eversense 365's exceptional accuracy a...
06-06 21:00
Insiders have been trading these 5 stocks: (($MPC)), (($COHR)), (($SENS)), (($K...
05-16 21:01
今日重点评级关注:Needham:维持Artiva Biotherapeutics"买入"评级,目标价从18美元升至41美元;HC Wainwright & Co.:维持SAB Biotherapeutics"买入"评级,目标价从7美元升至10美元
05-13 11:46
今日重点评级关注:HC Wainwright & Co.:维持Caribou Biosciences"买入"评级,目标价从9美元升至11美元;康托·菲茨杰拉德:维持Artiva Biotherapeutics"超配"评级,目标价从10美元升至40美元
05-12 12:36
Stifel analyst Jonathan Block maintains Senseonics Holdings (NASDAQ:SENS) with a Hold and lowers the price target from $9 to $8.
05-11 21:28
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Senseonics业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** 2026年第一季度净收入达到1,170万美元,较去年同期的630万美元实现85%的强劲增长,主要得益于Eversense 365新患者增长的持续势头以及更多业务转向盈利性更高的捆绑支付渠道。 **利润率情况:** 毛利率达到58%,毛利润为690万美元,较去年同期增加540万美元。排除一次性50万美元的原材料利用收益后,毛利率仍达到约54%的水平。 **亏损状况:** 净亏损为3,230万美元(每股亏损0.71美元),较去年同期的1,430万美元净
05-10 12:09
Senseonics Holdings (AMEX:SENS) raises FY2026 sales outlook from $58.000 million-$62.000 million to $60.000 million-$64.000 million vs $60.197 million estimate.
05-08 05:47
Senseonics Holdings ( ($SENS) ) has issued an announcement. On May 1, 2026, Sen...
05-05 05:15
Senseonics Holdings ( ($SENS) ) has provided an update. On April 30, 2026, Sens...
05-02 00:30
Shares of Senseonics Holdings Inc (NASDAQ:SENS) are tumbling Friday morning pricing an $80 million underwritten public offering late Thursday.
05-01 22:06